Nifty
:
24273.80
Sensex
:
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)
Nifty
Sensex
:
:
24273.80
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 500257 | NSE: LUPIN

NSE BSE
2185.35
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  2199.30
  •  2215.00
  •  2175.55
  •  2185.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  752681
  •  16521.96
  •  2402.90
  •  1493.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 91,953.44
  • 32.06
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 93,711.57
  • 0.40%
  • 5.57

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.92%
  • 0.30%
  • 5.10%
  • FII
  • DII
  • Others
  • 21.46%
  • 23.90%
  • 2.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.59
  • 3.51
  • 6.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 8.90
  • 77.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.25
  • 26.17
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.83
  • 35.91
  • 40.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.52
  • 3.93
  • 4.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.28
  • 18.24
  • 14.89

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
42.05
67.26
83.17
84.98
P/E Ratio
47.71
29.83
24.12
23.61
Revenue
19656
22372
25033
26518
EBITDA
3800
4989
5950
6161
Net Income
1914
3072
3740
3975
ROA
8.2
13.3
15.9
14.4
P/B Ratio
6.4
5.42
4.54
3.89
ROE
14.31
19.59
20.4
17.62
FCFF
2482.79
2038.49
3229.36
3633.8
FCFF Yield
2.64
2.17
3.43
3.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
5,767.71
5,197.41
10.97%
5,672.73
5,038.56
12.59%
5,600.33
4,814.06
16.33%
4,960.79
4,430.08
11.98%
Expenses
4,411.81
4,159.47
6.07%
4,332.37
4,120.80
5.13%
4,359.36
3,957.77
10.15%
3,964.03
3,852.31
2.90%
EBITDA
1,355.90
1,037.94
30.63%
1,340.36
917.76
46.05%
1,240.97
856.29
44.92%
996.76
577.77
72.52%
EBIDTM
23.51%
19.97%
23.63%
18.21%
22.16%
17.79%
20.09%
13.04%
Other Income
53.71
29.37
82.87%
42.29
40.40
4.68%
67.78
22.83
196.89%
29.34
37.27
-21.28%
Interest
66.89
74.01
-9.62%
70.87
80.64
-12.12%
68.01
85.67
-20.61%
71.29
92.55
-22.97%
Depreciation
271.45
257.20
5.54%
256.92
247.85
3.66%
247.71
234.66
5.56%
457.10
263.99
73.15%
PBT
1,071.27
736.10
45.53%
1,054.86
629.67
67.53%
993.03
558.79
77.71%
497.71
258.50
92.54%
Tax
212.41
117.40
80.93%
195.38
134.35
45.43%
187.49
105.46
77.78%
129.49
16.11
703.79%
PAT
858.86
618.70
38.82%
859.48
495.32
73.52%
805.54
453.33
77.69%
368.22
242.39
51.91%
PATM
14.89%
11.90%
15.15%
9.83%
14.38%
9.42%
7.42%
5.47%
EPS
18.74
13.46
39.23%
18.69
10.76
73.70%
17.57
9.94
76.76%
7.89
5.19
52.02%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
22,001.56
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
Net Sales Growth
12.94%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
 
Cost Of Goods Sold
6,729.89
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
Gross Profit
15,271.67
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
GP Margin
69.41%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
Total Expenditure
17,067.57
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
Power & Fuel Cost
-
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
% Of Sales
-
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
Employee Cost
-
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
% Of Sales
-
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
Manufacturing Exp.
-
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
% Of Sales
-
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
General & Admin Exp.
-
2,221.17
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
% Of Sales
-
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
Selling & Distn. Exp.
-
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
% Of Sales
-
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
Miscellaneous Exp.
-
286.55
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
835.48
% Of Sales
-
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
EBITDA
4,933.99
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
EBITDA Margin
22.43%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
Other Income
193.12
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
Interest
277.06
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
Depreciation
1,233.18
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
PBT
3,616.87
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
Tax
724.77
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
Tax Rate
20.04%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
PAT
2,892.10
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
PAT before Minority Interest
2,868.53
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
Minority Interest
-23.57
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
PAT Margin
13.14%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
PAT Growth
59.81%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
 
EPS
63.34
41.93
9.42
-33.47
26.61
-5.99
13.40
5.43
55.83
49.41
52.63

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
Share Capital
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
Total Reserves
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
Non-Current Liabilities
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
Secured Loans
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
Unsecured Loans
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
Long Term Provisions
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
Current Liabilities
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
Trade Payables
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
Other Current Liabilities
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
Short Term Borrowings
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
Short Term Provisions
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
Total Liabilities
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
Net Block
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
Gross Block
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
Accumulated Depreciation
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
Non Current Assets
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
Capital Work in Progress
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
Non Current Investment
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
Long Term Loans & Adv.
277.52
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
Other Non Current Assets
90.95
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
Current Assets
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
Current Investments
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
Inventories
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
Sundry Debtors
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
Cash & Bank
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
Other Current Assets
1,752.23
1,519.98
497.54
556.89
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
534.98
Short Term Loans & Adv.
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
Net Current Assets
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
Total Assets
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
PBT
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
Adjustment
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
Changes in Working Capital
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
Cash after chg. in Working capital
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
Net Fixed Assets
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
Net Investments
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
Others
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
Cash from Financing Activity
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
Net Cash Inflow / Outflow
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
Opening Cash & Equivalents
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
Closing Cash & Equivalent
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
ROA
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
ROE
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
ROCE
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
Fixed Asset Turnover
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
Receivable days
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
Inventory Days
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
Payable days
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
Cash Conversion Cycle
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
Total Debt/Equity
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
Interest Cover
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Lupin launches Eslicarbazepine Acetate Tablets
    8th May 2025, 09:28 AM

    Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity

    Read More
  • Lupin gets USFDA’s nod for Tolvaptan Tablets
    24th Apr 2025, 12:00 PM

    Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company

    Read More
  • Lupin’s arm recalling 2,724 bottles of Clomipramine hydrochloride Capsules
    23rd Apr 2025, 16:00 PM

    The company initiated the Class II recall on April 18, 2025

    Read More
  • Lupin’s arm achieves NABL accreditation across all greenfield labs
    23rd Apr 2025, 14:30 PM

    This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services

    Read More
  • Lupin gets EIR from USFDA for injectable facility in Nagpur
    17th Apr 2025, 16:09 PM

    The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024

    Read More
  • Lupin’s arm acquires Renascience Pharma in United Kingdom
    3rd Apr 2025, 09:19 AM

    With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary

    Read More
  • Lupin’s arm launches post-procedure home-based care guide with ACC
    24th Mar 2025, 12:30 PM

    This guide is based on the American College of Cardiology’s ‘Home-Based Care Workbook’

    Read More
  • Lupin’s arm wins CMO Award for Life Science Leadership in Drug Delivery
    22nd Mar 2025, 15:24 PM

    This award serves as a motivation to continue Nanomi's mission to revolutionize healthcare

    Read More
  • Lupin incorporates wholly owned subsidiary
    18th Mar 2025, 17:45 PM

    The company has incorporated wholly-owned subsidiary namely ‘Lupinlife Consumer Healthcare’

    Read More
  • Lupin receives USFDA’s tentative approval for Amifampridine Tablets
    17th Mar 2025, 13:00 PM

    This product would be manufactured at Lupin’s Goa facility in India

    Read More
  • Lupin launches Rivaroxaban Tablets in United States
    8th Mar 2025, 17:03 PM

    Rivaroxaban Tablets USP, 2.5 mg had estimated annual sales of $446 million in the U.S.

    Read More
  • Lupin gets EIR for Somerset manufacturing facility
    21st Feb 2025, 17:13 PM

    The company has received EIR from USFDA

    Read More
  • Lupin gets ‘A-’ leadership rating from CDP in two categories
    19th Feb 2025, 15:11 PM

    This rating reflects Lupin's leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey

    Read More
  • Lupin gets nod to incorporate wholly owned subsidiary
    12th Feb 2025, 10:19 AM

    The Board of Directors of the Company, at its meeting held on February 11, 2025, inter alia, considered and unanimously approved the same

    Read More
  • Lupin reports 39% rise in Q3 consolidated net profit
    12th Feb 2025, 09:40 AM

    Total consolidated income of the increased by 11.38% at Rs 5821.42 crore for Q3FY25

    Read More
  • Lupin - Quarterly Results
    12th Feb 2025, 00:45 AM

    Read More
  • Lupin gets nod from USFDA for Ipratropium Bromide Nasal Solution
    10th Feb 2025, 17:59 PM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin, Natco Pharma receive approval from USFDA for Bosentan Tablets for Oral Suspension
    10th Feb 2025, 15:38 PM

    Bosentan Tablets for Oral Suspension had estimated annual sales of $11 million in the U.S.

    Read More
  • USFDA completes pre-approval inspection at Lupin’s manufacturing facility in New Jersey
    3rd Feb 2025, 11:08 AM

    The inspection was carried out from January 28, 2025 to February 1, 2025, and concluded with zero 483 observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.